- Details
- Philip Koo and Alicia Morgans discuss the evolving role of nuclear medicine in the multidisciplinary care of patients receiving radium-223 for metastatic CRPC (Castration-Resistant Prostate Cancer). Dr. Koo advocates for the emergence of "nuclear oncology" as the fourth pillar in comprehensive cancer programs, emphasizing the need for enhanced communication and collaboration among medical oncologi...
|
- Details
- Ian Davis joins Alicia Morgans in discussing the overall survival (OS) outcomes in ENZAMET (ANZUP 1304), an international, cooperative group randomized phase three cooperative group, open label study, looking at the addition of enzalutamide, for patients with metastatic hormone-sensitive prostate cancer, commencing therapy. At this year's ASCO meeting, Ian Davis presented the updated OS findings f...
|
- Details
- Fred Saad joins Alicia Morgans in discussing the association between PSA response and overall survival (OS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase 3 ARASENS trial. In the ARASENS trial, the combination of darolutamide plus ADT and docetaxel significantly prolonged the time to PSA progression, and more patients receiving darolutamide vs placebo achieved...
|
- Details
- Cora Sternberg joins Alicia Morgans in discussing subgroup analyses of the phase 3 JAVELIN Bladder 100 trial which demonstrated that first-line avelumab maintenance + best supportive care (BSC) significantly prolonged overall survival compared to BSC alone in patients with advanced urothelial carcinoma that had not progressed during initial induction treatment with platinum-based chemotherapy. Drs...
|
- Details
- Cora Sternberg joins Alicia Morgans in a discussion on the treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) highlighting the ARASENS trial. The treatment landscape for mHSPC has become increasingly complex during the last several years. The ARASENS study along with PEACE-1 demonstrated that in patients eligible for treatment with chemotherapy, the addition of abiraterone...
|
- Details
- In this conversation, Matthew Cooperberg and Michael Hofman discuss areas of development in the diagnostic and theranostic spaces in prostate cancer management. Dr Hofman highlights the Federal Drug Administration (FDA) approval of PSMA 617, discusses its global accessibility, and the focus on patient selection for this treatment. The theraP trial was a phase III randomized study of 177Lu-PSMA-617...
|
- Details
- Alicia Morgans speaks with Robert Jones about the ATLANTIS Trial, focusing on an embedded randomization that studied the efficacy of Cabozantinib in urothelial carcinoma patients post-chemotherapy. Dr. Jones explains that the ATLANTIS platform aims to explore precision medicine in urothelial cancer and includes an "all-comers" arm to ensure broader patient participation. Unfortunately, the study f...
|
- Details
- Brittany Szymaniak sheds light on the critical role of germline genetic testing in prostate cancer. Dr. Szymaniak emphasizes that genetic testing is not just for metastatic cases but also for high-risk, very high-risk, and even localized disease. Patients with Ashkenazi Jewish ancestry and those with a family history of various cancers, including male breast cancer, should also be considered for t...
|
- Details
- Alicia Morgans and Brittany Szymaniak address the intricacies of germline genetic testing in prostate cancer. They delve into the current NCCN and AUA guidelines, noting challenges in aligning these with practical implementation. Both experts highlight the lag in prostate cancer genetic testing compared to other cancers like breast and ovarian. They explore alternative models for pre-test and post...
|
- Details
- Alicia Morgans and Brenda Martone delve into the critical role of germline and somatic genetic testing in managing metastatic prostate cancer. Dr. Martone emphasizes the NCCN guidelines, which recommend offering both types of testing to patients with high-risk or metastatic disease. The conversation highlights the importance of family history and the broader implications of germline mutations, not...
|
